Preclinical models and translational data demonstrate that BRAF/MEKi have an immunomodulatory effect on the tumour microenvironment (TME), further strengthening the biological rationale of combining the complimentary clinical profiles of BRAF/MEKi and CPI. Here, BRAF is linked to neoplasm.